Novo Nordisk A/S (NYSE:NVO) Shares Up 0.2%

Novo Nordisk A/S (NYSE:NVO) shares traded up 0.2% during trading on Friday . The company traded as high as $145.59 and last traded at $144.74. 433,317 shares traded hands during trading, a decline of 90% from the average session volume of 4,429,771 shares. The stock had previously closed at $144.49.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, June 17th. The Goldman Sachs Group began coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective for the company. Argus boosted their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a report on Tuesday. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Price Performance

The stock has a 50-day moving average of $134.16 and a two-hundred day moving average of $122.88. The firm has a market cap of $641.13 billion, a price-to-earnings ratio of 49.91, a price-to-earnings-growth ratio of 1.43 and a beta of 0.41. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion for the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. On average, analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pacific Center for Financial Services raised its holdings in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares in the last quarter. First PREMIER Bank bought a new position in Novo Nordisk A/S during the first quarter valued at about $25,000. CNB Bank bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $26,000. Dixon Mitchell Investment Counsel Inc. acquired a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $26,000. Finally, Orion Capital Management LLC acquired a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $26,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.